RPE65 and Leber congenital amaurosis 2: LuxturnaTMreceived FDA approval in December 2017 to treat Leber congenital amaurosis type 2 (LCA2), which is an inherited retinal disease (IRD) caused by mutations in the RPE65 gene, leading to severely impaired vision at birth.